Cyramza-话题@MedSci - 梅斯（MedSci）

#Cyramza#

8篇内容 | 868人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2077647, encodeId=de4820e7647a4, content=<a href='/topic/show?id=e92b5580bf' target=_blank style='color:#2F92EE;'>#Cyramza#</a>, objectTitle=FDA批准CYRAMZA（ramucirumab）一线治疗转移性EGFR突变非小细胞肺癌, objectType=article, longId=195114, objectId=ab2419511413, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab2419511413, replyNumber=0, likeNumber=82, createdTime=2020-08-16, rootId=0, userName=12498ca5m83暂无昵称, userId=32a12500167, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab2419511413, moduleTitle=FDA批准CYRAMZA（ramucirumab）一线治疗转移性EGFR突变非小细胞肺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ab2419511413)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2077645, encodeId=bf7020e76458f, content=<a href='/topic/show?id=e92b5580bf' target=_blank style='color:#2F92EE;'>#Cyramza#</a>, objectTitle=Eli Lilly的Cyramza作为转移性非小细胞肺癌的一线治疗达到了3期临床试验的主要终点, objectType=article, longId=162242, objectId=fef6162242d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fef6162242d9, replyNumber=0, likeNumber=85, createdTime=2019-10-15, rootId=0, userName=12498ca5m83暂无昵称, userId=32a12500167, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fef6162242d9, moduleTitle=Eli Lilly的Cyramza作为转移性非小细胞肺癌的一线治疗达到了3期临床试验的主要终点, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fef6162242d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2077646, encodeId=915020e7646b2, content=<a href='/topic/show?id=e92b5580bf' target=_blank style='color:#2F92EE;'>#Cyramza#</a>, objectTitle=FDA扩大了礼来的抗VEGFR2单抗Cyramza的适应症，用作肝癌患者的二线治疗, objectType=article, longId=165891, objectId=11a416589183, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11a416589183, replyNumber=0, likeNumber=117, createdTime=2019-05-26, rootId=0, userName=12498ca5m83暂无昵称, userId=32a12500167, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11a416589183, moduleTitle=FDA扩大了礼来的抗VEGFR2单抗Cyramza的适应症，用作肝癌患者的二线治疗, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=11a416589183)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2077644, encodeId=814a20e76444f, content=<a href='/topic/show?id=e92b5580bf' target=_blank style='color:#2F92EE;'>#Cyramza#</a>, objectTitle=Cyramza可改善晚期肝癌患者的存活率, objectType=article, longId=134489, objectId=a62013448915, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a62013448915, replyNumber=0, likeNumber=109, createdTime=2018-05-05, rootId=0, userName=12498ca5m83暂无昵称, userId=32a12500167, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a62013448915, moduleTitle=Cyramza可改善晚期肝癌患者的存活率, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a62013448915)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2077643, encodeId=1b3320e76433c, content=<a href='/topic/show?id=e92b5580bf' target=_blank style='color:#2F92EE;'>#Cyramza#</a>, objectTitle=胃癌里程碑：礼来重磅单抗Cyramza获欧盟批准胃癌二线治疗药物, objectType=article, longId=44605, objectId=b3bc446059f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3bc446059f, replyNumber=0, likeNumber=80, createdTime=2015-03-07, rootId=0, userName=12498ca5m83暂无昵称, userId=32a12500167, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3bc446059f, moduleTitle=胃癌里程碑：礼来重磅单抗Cyramza获欧盟批准胃癌二线治疗药物, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b3bc446059f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2077642, encodeId=7b1120e764279, content=<a href='/topic/show?id=e92b5580bf' target=_blank style='color:#2F92EE;'>#Cyramza#</a>, objectTitle=FDA批准礼来单抗Cyramza第3个适应症：非小细胞肺癌, objectType=article, longId=44300, objectId=82284430006, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82284430006, replyNumber=0, likeNumber=68, createdTime=2015-09-12, rootId=0, userName=12498ca5m83暂无昵称, userId=32a12500167, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82284430006, moduleTitle=FDA批准礼来单抗Cyramza第3个适应症：非小细胞肺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=82284430006)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2077641, encodeId=4af820e7641da, content=<a href='/topic/show?id=e92b5580bf' target=_blank style='color:#2F92EE;'>#Cyramza#</a>, objectTitle=礼来重磅单抗Cyramza再获FDA批准, objectType=article, longId=42363, objectId=66a0423637f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66a0423637f, replyNumber=0, likeNumber=78, createdTime=2014-11-20, rootId=0, userName=12498ca5m83暂无昵称, userId=32a12500167, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66a0423637f, moduleTitle=礼来重磅单抗Cyramza再获FDA批准, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=66a0423637f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2077640, encodeId=940c20e764060, content=<a href='/topic/show?id=e92b5580bf' target=_blank style='color:#2F92EE;'>#Cyramza#</a>, objectTitle=礼来重磅单抗药物Cyramza将年底上市欧盟, objectType=article, longId=40982, objectId=83ce409821d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83ce409821d, replyNumber=0, likeNumber=87, createdTime=2015-03-04, rootId=0, userName=12498ca5m83暂无昵称, userId=32a12500167, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83ce409821d, moduleTitle=礼来重磅单抗药物Cyramza将年底上市欧盟, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=83ce409821d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Cyramza

2020-05-29

12498ca5m83暂无昵称 (审核中...)

前往app查看评论内容

#Cyramza#

FDA批准CYRAMZA（ramucirumab）一线治疗转移性EGFR突变非小细胞肺癌

2020-08-16

12498ca5m83暂无昵称 (审核中...)

前往app查看评论内容

#Cyramza#

Eli Lilly的Cyramza作为转移性非小细胞肺癌的一线治疗达到了3期临床试验的主要终点

2019-10-15

12498ca5m83暂无昵称 (审核中...)

前往app查看评论内容

#Cyramza#

FDA扩大了礼来的抗VEGFR2单抗Cyramza的适应症，用作肝癌患者的二线治疗

2019-05-26

12498ca5m83暂无昵称 (审核中...)

前往app查看评论内容

#Cyramza#

Cyramza可改善晚期肝癌患者的存活率

2018-05-05

12498ca5m83暂无昵称 (审核中...)

前往app查看评论内容

#Cyramza#

胃癌里程碑：礼来重磅单抗Cyramza获欧盟批准胃癌二线治疗药物

2015-03-07

12498ca5m83暂无昵称 (审核中...)

前往app查看评论内容

#Cyramza#

FDA批准礼来单抗Cyramza第3个适应症：非小细胞肺癌

2015-09-12

12498ca5m83暂无昵称 (审核中...)

前往app查看评论内容

#Cyramza#

礼来重磅单抗Cyramza再获FDA批准

2014-11-20

12498ca5m83暂无昵称 (审核中...)

前往app查看评论内容

#Cyramza#

礼来重磅单抗药物Cyramza将年底上市欧盟

2015-03-04

科室
- - 订阅+
  - 更多科室
工具
服务